ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2020
Immunological dynamics after subcutaneous immunization with a squalene-based oil-in-water adjuvant.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Sex shapes CD64 expression and vaccine-induced monocytic responses.Biology of sex differences · 2026Article
- Immunogenicity of SARS-CoV-2 vaccine prototype based on virus-like particles of hepatitis B core antigen from genotype G and interleukin 12 expressing Semliki Forest virus as a genetic adjuvant.The Journal of general virology · 2026Article
- Synergistic Enhancement of Humoral and Cellular Immunity in Attenuated Live Vaccines Using Chemical Nanoadjuvants: Evaluation of Sustained-Release Formulations.Veterinary sciences · 2025Article
- MIP-3α-antigen fusion DNA vaccine enhances sex differences in tuberculosis model and alters dendritic cell activity early post vaccination.Scientific reports · 2025Article
- Vaccination with synthetic long peptide and CpG 2395 in AddaVax induces potent anti-tumor effects.Experimental biology and medicine (Maywood, N.J.) · 2025Article
- Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Article
- Exploiting Unique Features of Microneedles to Modulate Immunity.Advanced materials (Deerfield Beach, Fla.) · 2023Review
- Circular RNA vaccine induces potent T cell responses.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Article
- Dithranol as novel co-adjuvant for non-invasive dermal vaccination.NPJ vaccines · 2022Article
- Palmitoylated antigens for the induction of anti-tumor CD8Molecular therapy oncolytics · 2021Article
- Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination.Nature communications · 2021Article
- Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge.Frontiers in immunology · 2021Article
- Immunological dynamics after subcutaneous immunization with a squalene-based oil-in-water adjuvant.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinically successful adjuvant MF59 is used in seasonal influenza vaccines, which is proposed to enhance immunity by creating an immune-competent microenvironment in the muscle that allows recruitment of immune cells that drive adaptive immune responses. Here, we examined whether the clinically successful adjuvants MF59/AddaVax could be used for subcutaneous use and how antigen delivery can be synergized with cellular dynamics at the vaccination site. Subcutaneous injection of AddaVax leads to thickening of the skin, characterized by a neutrophil-monocyte recruitment sequence. Skin-infiltrating CCR2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.